10 May 2012 Posted in News Release By Press Office
Stephen Whitehead, ABPI Chief Executive, explains:
“With Neil’s introduction the ABPI is taking the opportunity to strengthen the link between our Innovation Board and our Board of Management. Supporting and encouraging innovation is the key role of our Innovation Board, but it is also a key consideration for the ABPI as a whole.
“We’re very grateful to all the effort and hard work John Stageman put into the Innovation Board, and I’m confident that we have the right person in Neil to continue taking us forward.”
Commenting on his appointment, Neil said:
"I’m delighted to have been appointed Chair of the ABPI Innovation Board at such a critical time for our industry. As the shape of our industry continues to rapidly change our fate lies in the ability to continually innovate. Our ambition must be to offer innovative new medicines and ground-breaking solutions that go beyond the drug. We must remain committed to enabling cutting-edge scientific research that is driven by the patients' needs but above all we should continue to focus on our core strength and offering, namely: innovation."
The ABPI is continuing to develop its Medical and Innovation capability whilst also increasing its level of engagement, and the recruitment process – managed by DHR International – to find a new Director to lead the Medical and Innovation team is currently underway. Previous Medical and Innovation Director, Dr Allison Jeynes-Ellis, left the ABPI in February of this year.
The ABPI Innovation Board was set up to develop a long term vision for pharmaceutical innovation in the UK and to boost our international competitive position.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064